Aldeyra Therapeutics stock rises 13% on Q2 beat with eyes on approval path for reproxalap [Seeking Alpha]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Seeking Alpha
Aldeyra Therapeutics stock rises 13% on Q2 beat with eyes on approval path for reproxalapAug. 05, 2022 12:21 PM ETAldeyra Therapeutics, Inc. (ALDX)By:RavikashSA News EditorZerborAldeyra Therapeutics (NASDAQ:~13%EPSNetlossexpenses."The second half of 2022 is highlighted by planned new drug applications in dry eye disease and primary vitreoretinal lymphoma, two diseases that are currently sub-optimally treated," stated Aldeyra President and CEO Todd Brady.Aldeyra's dry eye disease candidate Reproxalap met main goals in a trial and the company has Scheduled a meeting with the U.S. Food and Drug Administration (FDA) in Q3 to discuss NDA submission for the drug.The company also expects results from a phase 3 trial, dubbed GUARD, of ADX-2191 in Proliferative Vitreoretinopathy in H2 2022.As of June 30, cash equivalents, and marketable securities were $196.7M, which is expected to fund projected operating expenses through the end of 2023.Research and development expenses were $14.57M, compare
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseBusiness Wire
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.MarketBeat
ALDX
Earnings
- 5/2/24 - Miss
ALDX
Sec Filings
- 5/2/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/25/24 - Form EFFECT
- ALDX's page on the SEC website